(CIX: WRAL30)  1,171.56  up arrow+0.76  (0.07 %)  Updated: 05:15 PM EST, Nov 27 2015
(NQ: Apple)  117.81  down arrow-0.22  (-0.19 %)  Updated: 05:10 PM EST, Nov 27 2015
(NY: QUINTILES)  69.26  up arrow+0.75  (1.09 %)  Updated: 05:15 PM EST, Nov 27 2015
(OP: BASF SE)  82.65  down arrow-0.22  (-0.27 %)  Updated: 02:20 PM EST, Nov 27 2015
(NQ: BioCryst)  10.30  up arrow+0.07  (0.68 %)  Updated: 05:10 PM EST, Nov 27 2015
(NQ: BioDelivery)  6.03  up arrow+0.12  (2.03 %)  Updated: 05:10 PM EST, Nov 27 2015
(NQ: CEMP)  32.75  down arrow-0.06  (-0.18 %)  Updated: 05:10 PM EST, Nov 27 2015
(NQ: Cisco)  27.32  up arrow+0.08  (0.29 %)  Updated: 05:10 PM EST, Nov 27 2015
(NQ: Cree)  27.09  down arrow-0.01  (-0.04 %)  Updated: 05:10 PM EST, Nov 27 2015
(NQ: DARA)  0.92  up arrow+0.01  (1.09 %)  Updated: 05:10 PM EST, Nov 27 2015
(NY: EMC)  25.40  down arrow-0.02  (-0.08 %)  Updated: 05:15 PM EST, Nov 27 2015
(NQ: Extreme Networks)  4.34  up arrow+0.01  (0.23 %)  Updated: 05:10 PM EST, Nov 27 2015
(NQ: Facebook)  105.45  up arrow+0.04  (0.04 %)  Updated: 05:10 PM EST, Nov 27 2015
(NY: GLAXOSMITHKLINE)  40.96  up arrow+0.26  (0.64 %)  Updated: 05:15 PM EST, Nov 27 2015
(NQ: Alphabet)  750.26  up arrow+2.11  (0.28 %)  Updated: 05:10 PM EST, Nov 27 2015
(NY: IBM)  138.46  up arrow+0.46  (0.33 %)  Updated: 05:15 PM EST, Nov 27 2015
(NY: LH)  122.07  up arrow+0.25  (0.21 %)  Updated: 05:15 PM EST, Nov 27 2015
(OP: Lenovo Group)  20.92  down arrow-1.28  (-5.77 %)  Updated: 02:20 PM EST, Nov 27 2015
(NY: MRK)  53.96  up arrow+0.24  (0.45 %)  Updated: 05:15 PM EST, Nov 27 2015
(NQ: Microsoft)  53.93  up arrow+0.24  (0.45 %)  Updated: 05:10 PM EST, Nov 27 2015
(NQ: NetApp)  30.69  down arrow-0.07  (-0.23 %)  Updated: 05:10 PM EST, Nov 27 2015
(NY: NOVARTIS AG)  85.84  down arrow-0.11  (-0.13 %)  Updated: 05:15 PM EST, Nov 27 2015
(OP: Novozymes A/S)  47.71  up arrow+0.39  (0.82 %)  Updated: 02:20 PM EST, Nov 27 2015
(NY: Pfizer)  32.79  down arrow-0.08  (-0.24 %)  Updated: 05:15 PM EST, Nov 27 2015
(NQ: Pozen)  7.28  up arrow+0.21  (2.97 %)  Updated: 05:10 PM EST, Nov 27 2015
(NY: Red Hat)  82.50  down arrow-0.02  (-0.02 %)  Updated: 05:15 PM EST, Nov 27 2015
(NQ: BBRY)  7.82  down arrow-0.09  (-1.14 %)  Updated: 05:10 PM EST, Nov 27 2015
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  12.82  up arrow+0.05  (0.39 %)  Updated: 05:10 PM EST, Nov 27 2015

Posts tagged “Quintiles”

Updated 6:08 a.m. Tuesday

Validic signs Quintiles as a client, effective immediately

Validic Quintiles becomes the latest client of Validic. The CRO will leverage Validic's platform to enrich the research experience for biopharmaceutical customers, researchers and patients.

November 10

Quintiles contributes open source code to ResearchKit

Quintiles            Quintiles has added open source code to ResearchKit framework, making it easier for developers to leverage health care data. The source code is available on GitHub.

Tags: Quintiles
November 5

Quintiles executive chairman Dennis Gillings to step down

Dennis Gillings, Quintiles Founder (2015) Dennis Gillings, the founder and executive chairman of Quintiles will retire at the end of 2015. He'll remain on the board of directors. Jack M. Greenberg will succeed him.

Tags: Quintiles
October 28

Premium Lock Quintiles Q3 earnings top analysts estimates

Quintiles            Quintiles Transactional Holdings (NYSE:Q) reported third quarter earnings of $117.58 million or 94 cents a share, beating analyst expectations of 81 cents a share and a 44.6 percent increase compared to the same period last year.

October 20

Premium Lock Quintiles names new COO and CFO

Quintiles            Quintiles has named Kevin Gordon, currently serving as executive vice president, Operations and chief financial officer (CFO), has been promoted to chief operating officer (COO). The company also said Michael McDonnell is expected to join Quintiles in December 2015 as executive vice president, chief financial officer (CFO).

Tags: Quintiles
October 12

Premium Lock Quintiles wins clinical research site award

Quintiles            Quintiles has been awarded the Society for Clinical Research Sites' (SCRS) 2015 Clinical Research Organization Eagle Award.

September 29

Premium Lock Beyond Statins: 2015 was a benchmark year for lipid lowering research

Li-Jung Tai, associate medical director, Quintiles Today is World Heart Day and to celebrate, Quintiles will turn its Durham building red. It also offers this look at new choices in lipid lowering drugs and what may be coming in the future.

September 28

Premium Lock Quintiles named market leader in Phase IV services

Quintiles            Quintiles has been named the market leader in Phase IV services for the third year in a row. That's according to the 2015 CRO Quality Benchmarking - Phase IV Service Providers Report from Industry Standard Research (ISR).

Updated September 21

Premium Lock Alzheimer's Research: 100 years in the making

Alzheimer's inforgraphic Today (Monday, Sept. 21) is World Alzheimer's Day and Durham-based Quintiles offers, among its day-long events, this assessment of the problem and the progress made with hope for a solution.

Updated September 18

Premium Lock NC Economic development package; Most innovative universities; Alzheimer's Day; startup hiring

Bulldog In today's Bulldog update of technology news: NC economic development package passes; 3 NC universities on most innovative list; Quintiles plans for Alzheimer's Day Monday; health IT startup to expand.

Updated July 31

Premium Lock 14M PCs run Windows 10; SciQuest profitable; Quintiles investors selling $500M in shares; Google's 'no' to right-to-be-forgotten; LinkedIn tumbles

Bulldog Bulletin In today's wrapup of technology and life science news: Microsoft says 14 million computers are running Windows 10; SciQuest turns a profit; Quintiles investors are selling $500 million in shares; Google says "no" to right-to-be-forgotten in France; and LinkedIn shares tumble despite good quarterly results.

Updated July 29

Premium Lock Quintiles beats Street expectations despite impact of stronger dollar

Quintiles            Quintiles beats Wall Street analysts' expectations for revenue and earnings in the second quarter despite the impact of a stronger dollar on its overseas business. Will its stock rally on the news?

July 6

Premium Lock 'Humbled' veteran Quintiles exec gears up for new role as Q2 CEO

Q2 Solutions, the new life science services subsidiary launched by Quintiles and Quest Diagnostics, has a familiar face leading it as CEO: Costa Panagos, who has worked at Quintiles for the past 15 years. So why give up corporate security to take the new job? How does he feel about it? And what does Q2 offer in terms of improving healthcare? WTW Insiders get the exclusive details.

Costa Panagos Costa Panagos

Updated July 3

Premium Lock Will there be layoffs as well as new jobs as Quintiles' Q2 launches?

DNA      Quintiles' new joint venture with Quest formally launched Thursday with a work force of some 2,000 people. But will there be layoffs due to any overlap in job functions? Might there also be new jobs created? Let's take a look.

Updated July 2

Premium Lock Quintiles, Quest formally launch new clinical lab, drug testing company

Q2 Solutions, or "Q Squared Solutions," is formally launching today as a new clinical trials laboratory company owned by Quintiles and Quest Diagnostics. The new venture is led by a former Quintiles executive. The new company kicks off with 2,000 employees.

Costa Panagos Costa Panagos

June 30

Premium Lock An in-flight rescue: Quintiles physician saves passenger

When a medical emergency occurred on an international flight from London to India recently, the crew received a rapid response from a Quintiles physician and her husband- also a doctor. They saved a woman and helped her husband.

Dr. Vidya Kadam, left, adn Dr. Santosh Kadam Dr. Vidya Kadam, left, adn Dr. Santosh Kadam

June 15

Premium Lock Quintiles adds predictive analytics to drug development suite

Quintiles, the world's largest life science services company, is adding predictive analytics based on proprietary algorithms to its risk-based monitoring suite for clients seeking to develop drugs less expensively and faster through software solutions that can predict outcomes and potential safety issues.

June 5

Premium Lock Quintiles among few NC risers in latest Fortune 500

Fortune Quintiles is one of only four North Carolina companies that improved their standing in the 2015 Fortune 500 list. Quintiles also is one of only two N.C. life science firms to make the elite, just slightly below rival LabCorp.

May 14

Premium Lock Quintiles buying $250M in investor shares; BioCryst drug trial; AT&T-Hulu deal; new Leovo phones; Tumblr vs. bullying

Bulldog In today's Bulldog wrapup of technology and life science news: Quintiles is buying back $250 million in stock as investors sell shares; BioCryst prepares for new drug trial; AT&T makes a deal with Hulu; Lenovo is unveiling new phones in China; and Tumblr targets bullying.

Updated May 7

Premium Lock Piece by piece, Quintiles unveils details about new joint venture

Tom Pike, the CEO of Quintiles, must like to build with Legos or play with puzzles because he certainly is disclosing details about the giant's forthcoming joint venture with Quest one piece at a time. Here are a couple of recent samples for our Insiders.

Tom Pike Tom Pike

Techwire Inside Partners
The Skinny: A Blog by Rick Smith